STATEMENT OF ALLIANCE FOR PHARMACY COMPOUNDING CEO SCOTT BRUNNER, CAE, ON FDA’S ANNOUNCED INTENTION TO "take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs)”
STATEMENT OF ALLIANCE FOR PHARMACY COMPOUNDING CEO SCOTT BRUNNER, CAE, ON FDA’S ANNOUNCED INTENTION TO take decisive steps to restrict GLP-1 active ...





